Combinatorial Antitumor Activity of Oxaliplatin with Epigenetic Modifying Agents, 5-Aza-CdR and FK228, in Human Gastric Cancer Cells.
10.4062/biomolther.2018.061
- Author:
Jong Kook PARK
1
;
Jung Seon SEO
;
Suk Kyeong LEE
;
Kenneth K CHAN
;
Hyo Jeong KUH
Author Information
1. Department of Biomedical Science and Research Institute for Bioscience & Biotechnology, Hallym University, Chuncheon 24252, Republic of Korea.
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Combinatorial index;
EBV;
Zta;
Synergism;
Antagonism
- MeSH:
Antineoplastic Agents;
Cell Line;
DNA;
Drug Combinations;
Epigenomics*;
Herpesvirus 4, Human;
Histone Deacetylases;
Humans*;
Stomach Neoplasms*;
Triplets
- From:Biomolecules & Therapeutics
2018;26(6):591-598
- CountryRepublic of Korea
- Language:English
-
Abstract:
Epigenetic silencing is considered to be a major mechanism for loss of activity in tumor suppressors. Reversal of epigenetic silencing by using inhibitors of DNA methyltransferase (DNMT) or histone deacetylases (HDACs) such as 5-Aza-CdR and FK228 has shown to enhance cytotoxic activities of several anticancer agents. This study aims to assess the combinatorial effects of gene-silencing reversal agents (5-Aza-CdR and FK228) and oxaliplatin in gastric cancer cells, i.e., Epstein-Barr virus (EBV)-negative SNU-638 and EBV-positive SNU-719 cells. The doublet combinatorial treatment of 5-Aza-CdR and FK228 exhibited synergistic effects in both cell lines, and this was further corroborated by Zta expression induction in SNU-719 cells. Three drug combinations as 5-Aza-CdR/FK228 followed by oxaliplatin, however, resulted in antagonistic effects in both cell lines. Simultaneous treatment with FK228 and oxaliplatin induced synergistic and additive effects in SNU-638 and SNU-719 cells, respectively. Three drug combinations as 5-Aza-CdR prior to FK228/oxaliplatin, however, again resulted in antagonistic effects in both cell lines. This work demonstrated that efficacy of doublet synergistic combination using DNMT or HDACs inhibitors can be compromised by adding the third drug in pre- or post-treatment approach in gastric cancer cells. This implies that the development of clinical trial protocols for triplet combinations using gene-silencing reversal agents should be carefully evaluated in light of their potential antagonistic effects.
